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Thyroid metastases account for approximately 1.4-3% of all malignancies of the thyroid gland. Thyroid metastases
are most common in: clarocellular carcinoma of the kidney, lung cancer, breast cancer, malignant melanoma and
cancers of gastrointestinal tract. A rare situation is when thyroid metastasis is diagnosed before detecting primary
malignant focus and when it is the first manifestation of underlying disease. We present a case of 64-year-old male
with thyroid metastasis being the first manifestation of lung adenocarcinoma.
The authors emphasize that patients with the history of malignancy should undergo an ultrasound examination of
the thyroid gland in order to exclude a focal lesion, and if such lesion is detected, fine-needle aspiration biopsy is
recommended. The authors also point out that establishing final diagnosis of thyroid metastasis of cancer in other
organs is only possible on the basis of postoperative histopathology and immunohistochemistry.
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Goiter is the most common pathology of the thyroid
gland. Palpable focal lesions of the thyroid are found in
3-7% adults. Autopsy showed goiter in 50% of clinically
normal thyroid glands. The rate of cancer in multinodu-
lar goiter is estimated at approximately 5% [1]. Thyroid
cancer is the most common malignancy of endocrine
system. Its most frequent histologic type is papillary can-
cer followed by follicular cancer, accounting for approx.
80% and approximately 10% of all thyroid cancers, re-
spectively [2]. The thyroid gland may be the target for
metastases. Thyroid metastases make up approx. 1.4-3%
of all malignancies of the thyroid gland [3]. According to
autopsy results, the rate of thyroid metastases may be as
much as 8-times higher, and it is estimated even at 24%
in patients with generalized malignant disease [3,4]. This
difference between clinical reports and autopsy findings
is related to clinically mute micrometastases. Thyroid
metastases are most common in clarocellular carcinoma
of the kidney, lung cancer, breast cancer, cancers of
gastrointestinal tract and malignant melanoma [3-6]. In* Correspondence: aneknaj@go2.pl
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lished in the course of diagnostic investigations and the
assessment of newly diagnosed cancer advancement, or
in patients with the history of malignancy. Rarely have
thyroid metastases been diagnosed before detecting pri-
mary malignant focus and being its first manifestation
[3,6]. We present a case of 64-year-old male in whom
the diagnosis of focal lesion of the thyroid gland led to
the detection of lung adenocarcinoma.Case presentation
A 64-year-old male patient with hypertension, ischemic
heart disease, history of myocardial infarction in 1999
and lung tumors monitored in consecutive CT scans
attended a visit at Endocrine Outpatient Clinic because
of a palpable tumor in lower part of the neck on its right
side. Anomalies found in physical examination included
the enlargement of the right thyroid lobe with palpable
hard tumor with the diameter of approx. 4 cm and with-
out enlargement of cervical lymph nodes. Serum TSH
(thyroid stimulating hormone) level was 3.0 uIU/ml
(normal range 0.27-4.2 uIU/ml). An ultrasound examin-
ation of the thyroid gland showed a solid, hypoechogenic
focal lesion with microcalcifications in the right thyroidl Ltd. This is an Open Access article distributed under the terms of the Creative
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opsy material sampled from thyroid tumor suggested fol-
licular tumor. Immunocytochemistry proved that bioptate
reaction to calcitonin was negative. The patient was quali-
fied for surgery and in November 2009, right thyroidec-
tomy was performed. After surgery, the patient required
treatment with L-thyroxine at the dose of 37.5 ug/day.
The removed right thyroid lobe - size 7 x 4 x 3 cm with
the tumor diameter 3.5 cm – was subjected to histopath-
ology assessment. The tumor was encapsulated by con-
nective tissue and was made of cylindrical epithelial cells
with large nucleoli and mitotic figures. Immunohisto-
chemistry showed negative reaction to thyroglobulin,
CK20, calcitonin and CD34, while reactions to CK7 and
vimentin were positive. Based on histopathology and im-
munohistochemistry results, it was concluded that the
thyroid tumor was a metastasis, not a primary thyroid
cancer.
The search for primary malignant focus started with CT
of abdomen with contrast enhancement (January 2010),
which did not show any lesions in the liver, spleen, pan-
creas, adrenal glands, retroperitoneal space and small pelvis;
the lymph nodes in the regions covered by CT scan were
not enlarged, either. CT scan also covered the basal part of
the lungs showing the progression of subpleural tumor in
VII segment of right lung from 8 mm to 13 mm as com-
pared to CT scan of September 2009. Consequently, the pa-
tient was referred to the Department of Lung Diseases.
Fiberoptic bronchoscopy revealed a hypertrophic lesion in
S4 segment of left lung, which occluded bronchial lumen.
Histopathology revealed that the lesion was adenocarcin-
oma (adenocarcinoma typus bronchioalveolaris). The pa-
tient was qualified for chemotherapy. In 2011, the patient
developed bone metastases and therefore, radiotherapy was
started. In 2011, the patient attended regular follow-up
visits at Endocrine Outpatient Clinic every 3 months, he felt
well and despite advanced stage of the disease, his general
condition was good. In January 2012, check-up ultrasound
of the neck was performed showing three solid normoecho-
genic focal lesions in the left thyroid lobe – their sizes being
6 x 5 x 4 mm, 10 x 8 x 9 mm and 4 x 4 x 3 mm – and a
fragment of thyroid parenchyma size 4 x 3 mm was found
in the right lobe bed. Additionally, at mid-length of the
neck, on the right side and close to internal carotid artery,
there was a hypoechogenic, heterogeneous solid lesion, with
blurred contours and the size of 15 x 10 mm, which looked
suspicious in oncological terms. Fine-needle aspiration bi-
opsy of the largest focal lesion from the left thyroid lobe re-
vealed sheets of follicular cells without cytology features of
malignancy, while the biopsy of the lesion at the right side
showed non-small cell cancer cells. On his last visit at
Endocrine Outpatient Clinic in March 2012, the patient’s
general condition was good, and he remained in the state of
clinical and biochemical euthyreosis. He continued to betreated by pulmonologist. According to the information ob-
tained from patient’s family, the malignant disease pro-
gressed rapidly and the patient died in June 2012.
Discussion
Thyroid metastasis may be the first manifestation of ma-
lignancy in another organ [3,6,8]. Lam et al. analyzed a
group of 79 patients with thyroid metastases and found
that in 3 patients with lung cancer and 1 with breast
cancer, thyroid metastasis was the first clinical manifest-
ation of malignancy [8]. In clinical terms, the symptoms
of thyroid metastases do not differ from those of pri-
mary thyroid cancer. Neck circumference increases, thy-
roid gland gets harder or palpable thyroid tumors
develop. As the disease progresses, the patient may feel:
new or enlarging palpable thyroid nodule, pressure in
the neck, hoarseness, stridor, cough or dysphagia and
haemoptysis [3,6,9]. In the majority of patients with thy-
roid metastases, the function of the thyroid gland re-
mains normal but in rare cases, both hypothyroidism
and thyrotoxicosis have been described [3,9-12]. Miyakawa
M. et al. were the first to describe thyrotoxicosis in female
patient with thyroid metastasis of lung adenocarcinoma,
which resulted in massive damage of thyroid follicular
cells [10].
Thyroid metastases are rarely diagnosed based on cy-
tology assessment, especially in patients without clinical
features suggesting malignancy of another organ [5,6].
Histopathology and immunohistochemistry are decisive
in the diagnosis of thyroid metastasis. In patients with
postoperative diagnosis of thyroid metastasis based on
cytology of fine-needle aspiration biopsy material, fol-
licular neoplasm, neoplastic cells, atypical cell, as well as
primary cancer of the thyroid gland were suspected dur-
ing initial diagnosis of goiter [3,6,8,12]. Lam et al. were
the first to describe two cases of thyroid metastases,
which were diagnosed as primary thyroid cancer based
on cytology assessment, while in other two cases de-
scribed in this paper cytology results suggested thyroid
metastases but these were patients with the history of
malignancy [8]. Haraguchi et al. reported thyroid metas-
tasis of lung adenocarcinoma, imitating primary cancer
of the thyroid gland [13]. In a group of 15,122 patients
analyzed by Buła G. et al. and operated for various forms
of goiter, 10 patients were diagnosed with thyroid metas-
tases based on histopathology result. Preoperative cy-
tology assessment showed thyroid metastasis only in one
of these patients. In the remaining subjects, cytology re-
sults included follicular tumor, atypical cells, neoplastic
cells or epithelial cells and atypia [5].
The differentiation between primary thyroid cancer and
thyroid metastasis of lung cancer is particularly difficult,
because the thyroid gland and lungs have common em-
bryogenesis and therefore, they have similar profile in
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cal staining for TTF-1 (thyroid transcription factor-1),
thyroglobulin, CEA (carcinoembryonic antigen), cytokera-
tins 7 and 20, vimentin and histochemical staining for
mucus in cancer cells may be used in order to detect pri-
mary malignant focus [15,16]. The staining for CEA,
thyroglobulin and calcitonin of both cytology material and
tumor samples are the most useful in the differential diag-
nosis. Differentiated thyroid cancers exhibit positive reac-
tion to thyroglobulin. Medullary thyroid cancer cells have
positive reaction to calcitonin, CEA and chromogranin,
while they do not contain thyroglobulin [17].
Lung adenocarcinoma may form glandular structures,
which may resemble thyroid follicles, particularly in cy-
tology; therefore, just as in our case, the final diagnosis
of thyroid metastasis with indication of primary malig-
nant focus is based on histopathology and detailed ana-
lysis of immunohistochemical profile of neoplastic cells.
Conclusions
1. An ultrasound examination of the thyroid gland is
recommended in patients with neoplastic disease
and if focal lesion is found, fine-needle aspiration
biopsy is necessary.
2. Thyroid metastasis may be the first clinical
manifestation of neoplasm originating from another
organ.
3. Suspecting follicular neoplasm in cytology material
does not exclude the diagnosis of thyroid metastasis
of other organ malignancy in postoperative
histopathology.
4. The final diagnosis of thyroid metastasis with
indication of primary malignant focus is based on
histopathology and detailed analysis of
immunohistochemical profile of neoplastic cells.
Consent
Written informed consent was obtained from the patient's
daughter for the publication of this report and any accom-
panying images. Patient died before the publication.
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